These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 37457280)

  • 1. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
    Zhan M; Huang Z; Xu T; Xu X; Zheng H; Wu F
    Front Public Health; 2023; 11():1049947. PubMed ID: 37457280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
    Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
    Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
    Shi D; Liang X; Li Y; Chen L
    PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
    Peng Y; Wang L; Peng L; Liu Q; Yi L; Luo X; Li S; Qin S; Wan X; Tan C; Chen G
    Clin Ther; 2023 Oct; 45(10):965-972. PubMed ID: 37537015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
    Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
    Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.
    Yang J; Han J; Zeng N; Yan X
    Ther Adv Med Oncol; 2023; 15():17588359231169983. PubMed ID: 37228255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
    Yamashita T; Sohn JH; Tokunaga E; Niikura N; Park YH; Lee KS; Chae YS; Xu B; Wang X; Im SA; Li W; Lu YS; Aguilar CO; Nishijima S; Nishiyama Y; Sugihara M; Modi S; Tsurutani J
    Breast Cancer; 2024 Sep; 31(5):858-868. PubMed ID: 38884900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab deruxtecan
    Zhu Y; Liu K; Zhu X; Qin Q; Zhu H
    Front Pharmacol; 2022; 13():1025243. PubMed ID: 36386213
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.
    Lang Y; Wu B; Liu X
    Breast Cancer (Dove Med Press); 2022; 14():453-463. PubMed ID: 36532255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial.
    Zheng Z; Chen H; Cai H; Xu S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):387-395. PubMed ID: 38039117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Wang M; Wang K; Zhu H
    Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
    Hu S; Wu Y; Luan J; Wang S; Fan G
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
    Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
    Future Oncol; 2024; 20(18):1237-1250. PubMed ID: 38592002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
    N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.
    Mudumba R; Chan HH; Cheng YY; Wang CC; Correia L; Ballreich J; Levy J
    Value Health; 2024 Feb; 27(2):153-163. PubMed ID: 38042333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
    Zhan M; Xu T; Zheng H; He Z
    Front Public Health; 2022; 10():790225. PubMed ID: 35309225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.